Key result
End-stage heart failure prolongs right ventricular relaxation time by ~26 ms versus non-failing controls.
Why the study?
Does end-stage heart failure impair contractile force and relaxation kinetics in isolated human right ventricular myocardium compared to non-failing controls?
Does end-stage heart failure impair contractile force and relaxation kinetics in isolated human right ventricular myocardium compared to non-failing controls?
Absolute Event Rate: 155% vs 129%
p-value: p=<0.0001
Impaired relaxation kinetics, rather than deficits in resting active contractile force, are the hallmark of viable right ventricular myocardium in end-stage heart failure, suggesting therapies should target myocardial kinetics.
End-stage HF impairs RV relaxation kinetics without reducing resting force; leaves open whether kinetics-targeted therapies improve outcomes.
BACKGROUND: In patients with end-stage heart failure, the primary etiology often originates in the left ventricle, and eventually the contractile function of the right ventricle (RV) also becomes compromised. RV tissue-level deficits in contractile force and/or kinetics need quantification to understand involvement in ischemic and non-ischemic failing human myocardium. METHODS AND RESULTS: The human population suffering from heart failure is diverse, requiring many subjects to be studied in order to perform an adequately powered statistical analysis. From 2009-present we assessed live tissue-level contractile force and kinetics in isolated myocardial RV trabeculae from 44 non-failing and 41 failing human hearts. At 1 Hz stimulation rate (in vivo resting state) the developed active force was not different in non-failing compared to failing ischemic nor non-ischemic failing trabeculae. In sharp contrast, the kinetics of relaxation were significantly impacted by disease, with 50% relaxation time being significantly shorter in non-failing vs. non-ischemic failing, while the latter was still significantly shorter than ischemic failing. Gender did not significantly impact kinetics. Length-dependent activation was not impacted. Although baseline force was not impacted, contractile reserve was critically blunted. The force-frequency relation was positive in non-failing myocardium, but negative in both ischemic and non-ischemic myocardium, while the β-adrenergic response to isoproterenol was depressed in both pathologies. CONCLUSIONS: Force development at resting heart rate is not impacted by cardiac pathology, but kinetics are impaired and the magnitude of the impairment depends on the underlying etiology. Focusing on restoration of myocardial kinetics will likely have greater therapeutic potential than targeting force of contraction.
No takes yet. Share an insight, caveat, or question.
Chung et al. (2018) studied End-stage heart failure (n=85). End-stage heart failure vs. Non-failing donor myocardium was evaluated on 50% relaxation time (RT50) at 1 Hz stimulation (p=<0.0001). End-stage heart failure significantly impaired right ventricular myocardial relaxation kinetics compared to non-failing controls (RT50 155 ms vs 129 ms, p<0.0001) without impacting active force development at resting heart rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: